UTHR United Therapeutics Corporation
P/E
20.18
Forward P/E
16.42
Price/Sales
7.66
Beta
0.49
Div Yield
--
Market Cap
--
Company Analysis
Latest News
BlackRock Buys $2.87 Billion United Therapeutics Stake, Signaling Strong Institutional Confidence
BlackRock Inc. acquired 5,294,529 shares of United Therapeutics Corporation (NASDAQ:UTHR) during the second quarter. This investment is valued at approximately...
United Therapeutics Completes Tyvaso Phase 3 Enrollment, Targeting Lung Fibrosis
United Therapeutics completed enrollment for its TETON-PPF Phase 3 study. This multinational trial includes 754 patients to evaluate Tyvaso for the treatment...